缬沙坦与诺和锐30联合应用治疗2型糖尿病肾病的临床观察

Clinical Value of Valsartan and Lnsulin Aspart 30 in Treatment of Diabetic Nephropathy

目的探讨缬沙坦与诺和锐30联合应用对不同分期2型糖尿病肾病的治疗效果。方法 61例2型糖尿病肾病患者按尿蛋白定性,分为尿蛋白阴性而尿微量白蛋白排泄率≥20μg/min的微量白蛋白尿组(A组)38例和尿蛋白阳性的蛋白尿组(B组)23例,口服缬沙坦,根据血糖每日早晚2次餐前15 min皮下注射诺和锐30。治疗16周后观察缬沙坦与诺和锐30联合应用影响糖尿病肾病患者尿微量白蛋白排泄率情况。结果与治疗前比较,治疗后A组和B组的尿微量蛋白排泄率降低分别为(44.8±16.3)%和(29.0±23.7)%。两组比较差异有统计学意义(P>0.05)。结论缬沙坦与诺和锐30联合应用对2型糖尿病肾病患者的尿微量白蛋白有明显改善作用。

Objective To explore the value of valsartan and Insulin Aspart 30 on treating diabetic nephropathy of different stages. Methods 61 diabetic nephropathy patients were divided into 2 groups,according to the quantity of urenary albumin excretion rate（UAER）. The treatment was given 80 mg Valsartan daily and injection of Insulin Aspart 30. The course of treatment lasted for 16 week. Examine with the level of urinary albumin excretion rate. Results Urinary albumin excretion rate of Group a and group b after treatment were decreased （44.8±16.3）% and （29~23.7）%, respectively （P0.05）. Conclusion The Combination of valsartan and Insulin Aspart 30 is effective in the therapy of diabetic nephropathy, which can decrease urinary microalbumin.